Accès gratuit
Med Sci (Paris)
Volume 20, Numéro 3, Mars 2004
Page(s) 291 - 297
Section M/S revues
Publié en ligne 15 mars 2004
  1. Davies SW, Marchant B, Lyons JP. Irregular coronary lesion morphology after thrombolyis predicts early clinical instability. J Am Coll Cardiol 1991; 18 : 669–74. [Google Scholar]
  2. Theroux P, Fuster V. Acute coronary syndromes. Unstable angina and non-Q-wave myocardial infarction. Circulation 1998; 97 : 1195–206. [Google Scholar]
  3. Braunwald E, Antman EM, Califf RM, et al. ACC/AHA Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction, 2002. Summary article : a report of the American college of cardiology/American heart association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 2002; 106 : 1893–900. [Google Scholar]
  4. Verstaete M. A European view on the North American fifth consensus on antithrombotic therapy. Chest 2000; 117 : 1755–70. [Google Scholar]
  5. ISIS-2 collaborative group. Randomized trial of IV streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988; 330 : 1287–94. [Google Scholar]
  6. The clopidogrel in unstable angina to prevent recurrent events trials investigators (CURE). Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 : 494–502. [Google Scholar]
  7. Steinhubl SR, Berger S, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 2002; 288 : 2411. [Google Scholar]
  8. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glyco-protein IIb/IIIa inhibitors in acute coronary syndromes : a meta-analysis of all major randomised clinical trials. Lancet 2002; 359 : 189–98. [Google Scholar]
  9. The EPISTENT investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998; 352 : 87–92. [Google Scholar]
  10. The ESPRIT investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT) : a randomised, placebo-controlled trial. Lancet 2000; 356 : 2037–44. [Google Scholar]
  11. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344 : 1895–903. [Google Scholar]
  12. The GUSTO V investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition : the GUSTO V randomised trial. Lancet 2001; 357 : 1905–14. [Google Scholar]
  13. The Assessment of the safety and efficacy of a new thrombolytic regimen (ASSENT)-3 investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab or unfractionated heparin : the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358 : 605–13. [Google Scholar]
  14. Cohen M, Theroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin : the ACUTE (antithrombotic combination using tirofiban and enoxaparin) II study. Am Heart J 2002; 144 : 470–7. [Google Scholar]
  15. Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003; 107 : 238–44. [Google Scholar]
  16. Dalby M, Montalescot G, Sollier CB, et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol 2004; 43 : 162–8. [Google Scholar]
  17. Cannon CP, Weintraub SW, Demopoulos L, et al. A comparison of invasive versus conservative strategy in patients with unstablecoronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344 : 1879–87. [Google Scholar]
  18. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344 : 1888–94. [Google Scholar]
  19. Collet JP, Montalescot G, Fine E, et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol 2003; 41 : 8–14. [Google Scholar]
  20. Sharma SK, Kini AS, Perez N, et al. Tirofiban, eptifibatide and abciximab in minimizing myocardial damage during high-risk coronary intervention : final results of the TEAM pilot trial. J Am Coll Cardiol 2002; 39 (suppl A) : 73A (abstract 887-5). [Google Scholar]
  21. Gum PA, Kottle-Marchant K, Welch PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41 : 961–5. [Google Scholar]
  22. Collet JP, Himbert D, Steg PG. Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol 2000; 76 : 257–8. [Google Scholar]
  23. Samama CM, Bastien O, Forestier F, et al. Antiplatelet agents in the perioperative period : expert recommendations of the French society of anesthesiology and intensive care (SFAR) 2001. Summary statement. Can J Anaesth 2002; 49 : S26–35. [Google Scholar]
  24. The EPILOG investigators. Platelets glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularzation. N Engl J Med 1997; 336 : 1689–96. [Google Scholar]
  25. The Epic investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994; 330 : 956–61. [Google Scholar]
  26. The CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina : the CAPTURE study. Lancet 1997; 349 : 1429–35. [Google Scholar]
  27. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and primary PTCA organization and randomized trial (RAPPORT) investigators. Circulation 1998; 98 : 34–41. [Google Scholar]
  28. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346 : 957–66. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.